MedTrace Logo

Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders

NCT03626285 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-01-02

No results posted yet for this study

Summary

This expanded access protocol studies bone marrow transplantation using CD34-selected stem cells from related or unrelated donors in treating participants with cancer or other disorders. Stem cells collected from the donor will be processed using a new device called CliniMACS CD34 Reagent System which marks the blood cells collected from the donor with a special protein called "antibody" that tags only the donor stem cells, sorting out other cells of the blood and immune system. This is done to remove, at least partially, some of the T cells. T cells are the cells in the blood that work as scavengers of the immune system deciding what belongs and what does not. These cells can sometimes cause rejection of the donor graft or a condition called graft-versus host disease (GVHD), where the donor cells can attack the body of the recipient. A bone marrow transplantation using CD34-selected stem cells may reduce the risk of these unwanted side effects of transplant as much as possible.

Conditions

  • Benign Neoplasm
  • Bone Marrow Transplantation Recipient
  • Hematopoietic Cell Transplantation Recipient
  • Malignant Neoplasm

Interventions

PROCEDURE

Bone Marrow Transplantation

Undergo BMT

DEVICE

CliniMACS CD34 Reagent System

CD34 selection ex vivo

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Receive CD34-selected peripheral blood stem cells from related or unrelated donors

Sponsors & Collaborators

  • Oregon Health and Science University

    collaborator OTHER

  • OHSU Knight Cancer Institute

    lead OTHER

Principal Investigators

  • Eneida Nemecek, MD · OHSU Knight Cancer Institute

Eligibility

Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03626285 on ClinicalTrials.gov